The Can-Do Varicose Vein Treatment Your Clinic Needs
From tortuosity to the great saphenous vein (GSV), Varithena goes where thermal can’t and enhances results where thermal can.1
The Essential NTNT Tool
Varithena is FDA-approved for treating varicose veins caused by problems with the great saphenous vein (GSV) and related veins in the leg’s GSV system both above and below the knee. Unique CPT codes and a 30-day shelf life make Varithena a valuable and efficient way to treat more patients safely—without compromising on outcomes.
Procedure takes less than one hour
Varithena procedures have been performed
Only one or two needle sticks per treatment
Take Action
Tortuous veins. Large veins. Small veins. Recurrent symptoms. These patients walk through your clinic every day. Treat them comfortably—and reliably—with Varithena.
Have questions?
.jpg)
Varithena Case Studies
See what your peers are saying about Varithena treatment, how the treatment process worked for them and post-treatment results.
Support to Help You Succeed
Find resources you need to be Varithena certified and join a searchable Physician Finder database. You’ll also find reimbursement and coverage information.
References
- Vasquez M, et al. Phlebology. 2017;32:272-281.
- Patients reporting pain at injection or application site in clinical trials was 4.0%. BSC data on file.
Indications
Varithena® (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
Important Safety Information
The use of Varithena® is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.Varithena® can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.Physicians administering Varithena® must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena®.
See Full Prescribing Information for Varithena®